EXPAREL is a sterile, non-pyrogenic aqueous suspension of multivesicular liposomes comprising bupivacaine that is white or off-white and free of preservatives. The concentration of bupivacaine is 13.3 mg/mL. Bupivacaine is extracted from the multivesicular liposomes over time after EXPAREL is injected into soft tissue.
MARKET SCOPE
The "Global Bupivacaine Liposome Injectable Suspension Market Analysis to 2028" is a specialized and in-depth study of the food and beverages industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Bupivacaine Liposome Injectable Suspension market with detailed market segmentation by type, end use, and geography. The report provides key statistics on the market status of the leading Bupivacaine Liposome Injectable Suspension market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the global Bupivacaine Liposome Injectable Suspension market is segmented into 20ml, 10ml.
- On the basis of end use, the market is segmented into Veterinary, Human.
Drivers-
- With increasing cases of obesity all over the globe
- Increasing binge eating and consumption of junk foods, neglect towards regular exercise, rising levels of stress
- High cost of drug
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Bupivacaine Liposome Injectable Suspension market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Bupivacaine Liposome Injectable Suspension market in these regions.
IMPACT OF COVID-19 ON BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION MARKET
Several treatment regimens are being tested around the world in an attempt to find a safe solution for Covid-19. One treatment choice is to use hydroxychloroquine, and another is to use antiviral drugs used in HIV disease management. Many of these tactics increased demand for modern antivirals and antimalarial drugs. This has consequences for pharmaceutical companies since an off-label indication for these drug classes must be created. For the time being, the WHO has not prescribed any of these approaches and has made no determination as to which is superior.
MARKET PLAYERS
The report covers key developments in the Bupivacaine Liposome Injectable Suspension market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Bupivacaine Liposome Injectable Suspension market are anticipated to lucrative growth opportunities in the future with the rising demand for Bupivacaine Liposome Injectable Suspension in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Bupivacaine Liposome Injectable Suspension market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Pacira Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Merck and Co.
- Cipla, Inc.
- Cadila Pharmaceuticals
- SRS Pharmaceuticals Pvt. Ltd.
- EXPAREL
- Pacira